New data for Kalydeco for G551D mutation, R117H mutation and non-G551D mutation of Cystic Fibrosis announced at ECFS meeting - Vertex

Vertex Pharmaceuticals Incorporated announced the presentation of new Kalydeco (ivacaftor) data at the 37th European Cystic Fibrosis Society (ECFS) Conference, June 11-14, 2014, in Gothenburg, Sweden. New data from an analysis of Phase III and long-term extension studies in people with Cystic Fibrosis (CF) who have the G551D mutation showed that treatment with Kalydeco reduced the annual loss of lung function by half over three years compared to similar untreated CF patients. In addition, the first data from a rollover study following the Phase III KONDUCT study in people with the R117H mutation confirmed earlier results that demonstrated lung function improvements in people ages 18 and older. New data were also presented for the first time from the second part of the Phase III KONNECTION study in people with certain non-G551D gating mutations and showed that previously reported lung function improvements were maintained through 24 weeks of treatment.